CRANBURY, N.J. & STONY BROOK, N.Y.--(BUSINESS WIRE)--Cornerstone Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has received clearance from the US Food and Drug Administration (FDA) to begin a Phase I/II clinical trial evaluating the safety and early efficacy of its first-in-class Altered Energy Metabolism-Directed (AEMD) compound, CPI-613, in a variety of cancer types.
